[
  {
    "ts": null,
    "headline": "Big Tech earnings, Fed meeting, Trump & Xi meet: What to Watch",
    "summary": "Market Domination Overtime host Josh Lipton previews several of the biggest stories to come next week, including earnings results from Magnificent Seven companies Microsoft (MSFT), Amazon (AMZN), Apple (AAPL), Alphabet (GOOG, GOOGL), and Meta Platforms (META); Federal Reserve officials convening for their October FOMC meeting; and President Trump is meeting Chinese President Xi Jinping in South Korea as the government shutdown nears its fifth week. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
    "url": "https://finnhub.io/api/news?id=22c6dea8ce7264df11ed68c9230b2856ba3cd84794842af25c6654197546a9dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761346800,
      "headline": "Big Tech earnings, Fed meeting, Trump & Xi meet: What to Watch",
      "id": 137215915,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Market Domination Overtime host Josh Lipton previews several of the biggest stories to come next week, including earnings results from Magnificent Seven companies Microsoft (MSFT), Amazon (AMZN), Apple (AAPL), Alphabet (GOOG, GOOGL), and Meta Platforms (META); Federal Reserve officials convening for their October FOMC meeting; and President Trump is meeting Chinese President Xi Jinping in South Korea as the government shutdown nears its fifth week. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
      "url": "https://finnhub.io/api/news?id=22c6dea8ce7264df11ed68c9230b2856ba3cd84794842af25c6654197546a9dd"
    }
  },
  {
    "ts": null,
    "headline": "Adverum Biotechnologies Buyout by Eli Lilly Represents 'Best Possible Outcome' for Company, Mizuho Says",
    "summary": "Adverum Biotechnologies' (ADVM) deal to be acquired by Eli Lilly (LLY) represents a likely \"best pos",
    "url": "https://finnhub.io/api/news?id=a298f2116b077f1aa15ad3ca0049f7899eb3248650b4ca052939d66e47d94622",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761323636,
      "headline": "Adverum Biotechnologies Buyout by Eli Lilly Represents 'Best Possible Outcome' for Company, Mizuho Says",
      "id": 137215916,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Adverum Biotechnologies' (ADVM) deal to be acquired by Eli Lilly (LLY) represents a likely \"best pos",
      "url": "https://finnhub.io/api/news?id=a298f2116b077f1aa15ad3ca0049f7899eb3248650b4ca052939d66e47d94622"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Stocks Rise After Lower-Than-Expected CPI; Intel Q3 EPS, Revenue Top Expectations",
    "summary": "All three major US stock indexes were up in late-morning trading Friday after the latest consumer pr",
    "url": "https://finnhub.io/api/news?id=206b22a101c33b6dfc14e0c4e00ef245caa6a21b63f6266f840083be5db4b016",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761321273,
      "headline": "Top Midday Stories: Stocks Rise After Lower-Than-Expected CPI; Intel Q3 EPS, Revenue Top Expectations",
      "id": 137215917,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were up in late-morning trading Friday after the latest consumer pr",
      "url": "https://finnhub.io/api/news?id=206b22a101c33b6dfc14e0c4e00ef245caa6a21b63f6266f840083be5db4b016"
    }
  },
  {
    "ts": null,
    "headline": "NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?",
    "summary": "Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.",
    "url": "https://finnhub.io/api/news?id=ed2cfc0cf8cc3977258c0156ea46c87d7a12beeba3883b39dc44264d2f813ccf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761320340,
      "headline": "NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?",
      "id": 137215918,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.",
      "url": "https://finnhub.io/api/news?id=ed2cfc0cf8cc3977258c0156ea46c87d7a12beeba3883b39dc44264d2f813ccf"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's new chairman has 'carte blanche' after board clear-out",
    "summary": "STORY: A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation.It's rattling investors despite calls for stronger leadership at the drugmaker behind weight-loss treatment Wegovy.Once Europe's most valuable firm thanks to the blockbuster obesity drug, Novo Nordisk has stumbled in the last year.Slowing sales and intensifying competition from U.S. rival Eli Lilly have eroded its market share.The Novo Nordisk Foundation holds more than three-quarters of the firm's voting shares.This week it pushed out Novo's board chairman and independent members for not acting quickly enough to stem the decline in its key U.S. market.Foundation chair Lars Rebien Sorensen - a former long-time Novo chief executive - will also become the company board chairman.The dual role is unprecedented in the firm's history.One analyst told Reuters that the move showed the Foundation was in full control.The Novo Nordisk Foundation says on its website that it plays an \"arm's length\" role in the company.It was set up to ensure financial and strategic stability of the Novo Group.While advancing scientific research and humanitarian causes.Novo's shares are down around 5% since the board shake-up.Extending a decline that has seen the stock lose two-thirds of its value since a 2024 peak.Its CEO is now leading a sweeping restructuring, including thousands of job cuts.",
    "url": "https://finnhub.io/api/news?id=aec7f3934ee5451099146881197cae26c230768dc22ef348aeb23afe23a0a8ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761320051,
      "headline": "Novo Nordisk's new chairman has 'carte blanche' after board clear-out",
      "id": 137215919,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation.It's rattling investors despite calls for stronger leadership at the drugmaker behind weight-loss treatment Wegovy.Once Europe's most valuable firm thanks to the blockbuster obesity drug, Novo Nordisk has stumbled in the last year.Slowing sales and intensifying competition from U.S. rival Eli Lilly have eroded its market share.The Novo Nordisk Foundation holds more than three-quarters of the firm's voting shares.This week it pushed out Novo's board chairman and independent members for not acting quickly enough to stem the decline in its key U.S. market.Foundation chair Lars Rebien Sorensen - a former long-time Novo chief executive - will also become the company board chairman.The dual role is unprecedented in the firm's history.One analyst told Reuters that the move showed the Foundation was in full control.The Novo Nordisk Foundation says on its website that it plays an \"arm's length\" role in the company.It was set up to ensure financial and strategic stability of the Novo Group.While advancing scientific research and humanitarian causes.Novo's shares are down around 5% since the board shake-up.Extending a decline that has seen the stock lose two-thirds of its value since a 2024 peak.Its CEO is now leading a sweeping restructuring, including thousands of job cuts.",
      "url": "https://finnhub.io/api/news?id=aec7f3934ee5451099146881197cae26c230768dc22ef348aeb23afe23a0a8ce"
    }
  },
  {
    "ts": null,
    "headline": "Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs",
    "summary": "Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs.",
    "url": "https://finnhub.io/api/news?id=fef1e73965e5b9794217b3c7ef7483d653b03c44ce7e464915489e38b2911be2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761319860,
      "headline": "Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs",
      "id": 137214515,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs.",
      "url": "https://finnhub.io/api/news?id=fef1e73965e5b9794217b3c7ef7483d653b03c44ce7e464915489e38b2911be2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Acquire Eye Gene Therapy Developer Adverum Biotechnologies",
    "summary": "Eli Lilly (LLY) has agreed to acquire Adverum Biotechnologies (ADVM), which is developing a therapy",
    "url": "https://finnhub.io/api/news?id=3e7bf29008da3d43eee9e40fc0f005b2fe065c3cffdbd0918b7c8dfcb00baeb3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761318899,
      "headline": "Eli Lilly to Acquire Eye Gene Therapy Developer Adverum Biotechnologies",
      "id": 137215921,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) has agreed to acquire Adverum Biotechnologies (ADVM), which is developing a therapy",
      "url": "https://finnhub.io/api/news?id=3e7bf29008da3d43eee9e40fc0f005b2fe065c3cffdbd0918b7c8dfcb00baeb3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to buy Adverum, General Dynamics stock hits new record",
    "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Eli Lilly's (LLY) deal to acquire Adverum Biotechnologies (ADVM), gold miner Newmont's (NEM) cost-cutting initiatives, and General Dynamics (GD) shares moving to an all-time record high following its latest earnings results fueled by jet demand. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=f16138e64b7e4f3d11146ba6ba48005b2f834a8c801ec84912599f9e766e2cfa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761317210,
      "headline": "Eli Lilly to buy Adverum, General Dynamics stock hits new record",
      "id": 137215922,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Eli Lilly's (LLY) deal to acquire Adverum Biotechnologies (ADVM), gold miner Newmont's (NEM) cost-cutting initiatives, and General Dynamics (GD) shares moving to an all-time record high following its latest earnings results fueled by jet demand. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=f16138e64b7e4f3d11146ba6ba48005b2f834a8c801ec84912599f9e766e2cfa"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Decade-Low Valuation Meets A Billion-Patient Market",
    "summary": "Discover why Novo Nordisk (NVO) is rated Strong Buy despite risks.",
    "url": "https://finnhub.io/api/news?id=8ad8fa35202300729f841ad03adff04d95779e02841ecffadb60cf8d7ffff105",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761315841,
      "headline": "Novo Nordisk: Decade-Low Valuation Meets A Billion-Patient Market",
      "id": 137203083,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2173389488/image_2173389488.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why Novo Nordisk (NVO) is rated Strong Buy despite risks.",
      "url": "https://finnhub.io/api/news?id=8ad8fa35202300729f841ad03adff04d95779e02841ecffadb60cf8d7ffff105"
    }
  },
  {
    "ts": null,
    "headline": "Elevance Health Inc: A Key Exit in Eaton Vance Worldwide Health Sciences Fund's Q3 2025 Portfolio",
    "summary": "Insights into Eaton Vance's Strategic Moves in the Healthcare Sector",
    "url": "https://finnhub.io/api/news?id=6c03f1f90caf6a240b0d949293028ff77c68d06016f41d60a3b06cd2e82e3f27",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761314439,
      "headline": "Elevance Health Inc: A Key Exit in Eaton Vance Worldwide Health Sciences Fund's Q3 2025 Portfolio",
      "id": 137215923,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Insights into Eaton Vance's Strategic Moves in the Healthcare Sector",
      "url": "https://finnhub.io/api/news?id=6c03f1f90caf6a240b0d949293028ff77c68d06016f41d60a3b06cd2e82e3f27"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?",
    "summary": "INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.",
    "url": "https://finnhub.io/api/news?id=199d96a4c2cc628ad220db91a6e2d42c2ddd10aa9a7ae393554318f550bf118a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761314220,
      "headline": "Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?",
      "id": 137215924,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.",
      "url": "https://finnhub.io/api/news?id=199d96a4c2cc628ad220db91a6e2d42c2ddd10aa9a7ae393554318f550bf118a"
    }
  },
  {
    "ts": null,
    "headline": "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings",
    "summary": "LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.",
    "url": "https://finnhub.io/api/news?id=6628e9017c13810d4e5dd87125653beb0cd4b2cd310bbc6c24dc78e8d13c7010",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761312540,
      "headline": "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings",
      "id": 137215925,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.",
      "url": "https://finnhub.io/api/news?id=6628e9017c13810d4e5dd87125653beb0cd4b2cd310bbc6c24dc78e8d13c7010"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Acquire Adverum Biotechnologies for Up to $12.47 a Share",
    "summary": "Eli Lilly (LLY) has agreed to acquire Adverum Biotechnologies (ADVM) including its lead product cand",
    "url": "https://finnhub.io/api/news?id=9652648afa6efc5d250fd9091eda914557d563f1cdfafae0519db3d66bbd73c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761310587,
      "headline": "Eli Lilly to Acquire Adverum Biotechnologies for Up to $12.47 a Share",
      "id": 137215926,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) has agreed to acquire Adverum Biotechnologies (ADVM) including its lead product cand",
      "url": "https://finnhub.io/api/news?id=9652648afa6efc5d250fd9091eda914557d563f1cdfafae0519db3d66bbd73c6"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to Acquire Adverum Biotechnologies",
    "summary": "Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adverum Biotechnologies, Inc. (\"Adverum\"), including its lead product candidate, Ixo-vec.",
    "url": "https://finnhub.io/api/news?id=0e2904af3238969fa32c74259f6517d56413dce2ebc403176d4884d3fc98f1a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761309000,
      "headline": "Lilly to Acquire Adverum Biotechnologies",
      "id": 137215927,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adverum Biotechnologies, Inc. (\"Adverum\"), including its lead product candidate, Ixo-vec.",
      "url": "https://finnhub.io/api/news?id=0e2904af3238969fa32c74259f6517d56413dce2ebc403176d4884d3fc98f1a5"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Eli Lilly: “They Need to Have Something Else to Come Out”",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently answered questions about. Answering a caller’s query about the stock during the episode, Cramer said: “Here’s the problem with Lilly: they need to have something else to come out. They need something that’s big that the insurance companies will cover, for their […]",
    "url": "https://finnhub.io/api/news?id=d2862ab329fcaae137284f4137dc7701376e9fdb931acf853f1d8c3970187311",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761307964,
      "headline": "Jim Cramer on Eli Lilly: “They Need to Have Something Else to Come Out”",
      "id": 137215928,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently answered questions about. Answering a caller’s query about the stock during the episode, Cramer said: “Here’s the problem with Lilly: they need to have something else to come out. They need something that’s big that the insurance companies will cover, for their […]",
      "url": "https://finnhub.io/api/news?id=d2862ab329fcaae137284f4137dc7701376e9fdb931acf853f1d8c3970187311"
    }
  },
  {
    "ts": null,
    "headline": "Adverum, hammered by gene therapy downturn, sells to Lilly in unusual deal",
    "summary": "Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the company’s previous closing share price.",
    "url": "https://finnhub.io/api/news?id=1594dd7ecc28871b01b01021b6ae38722132b815a41dd4362ea907eb3c032ac1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761306240,
      "headline": "Adverum, hammered by gene therapy downturn, sells to Lilly in unusual deal",
      "id": 137215929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the company’s previous closing share price.",
      "url": "https://finnhub.io/api/news?id=1594dd7ecc28871b01b01021b6ae38722132b815a41dd4362ea907eb3c032ac1"
    }
  },
  {
    "ts": null,
    "headline": "3 Stocks Estimated To Be Undervalued By Up To 29.8%",
    "summary": "As major U.S. stock indexes recently ended lower amidst ongoing earnings reports and renewed U.S.-China trade tensions, investors are keenly observing market fluctuations for potential opportunities. In such an environment, identifying undervalued stocks can be a strategic approach, as these equities might offer a margin of safety and potential for appreciation when market conditions stabilize or improve.",
    "url": "https://finnhub.io/api/news?id=ad26bd8b9d005d28409510fd606780117579e0c6866273a68ac7788cbf817b74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761305891,
      "headline": "3 Stocks Estimated To Be Undervalued By Up To 29.8%",
      "id": 137204654,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As major U.S. stock indexes recently ended lower amidst ongoing earnings reports and renewed U.S.-China trade tensions, investors are keenly observing market fluctuations for potential opportunities. In such an environment, identifying undervalued stocks can be a strategic approach, as these equities might offer a margin of safety and potential for appreciation when market conditions stabilize or improve.",
      "url": "https://finnhub.io/api/news?id=ad26bd8b9d005d28409510fd606780117579e0c6866273a68ac7788cbf817b74"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis",
    "summary": "New results show Eli Lilly and Company's (NYSE: LLY) EBGLYSS (lebrikizumab-lbkz) sustained similar levels of skin clearance when administered as a single injection of 250 mg once every eight weeks (Q8W) compared with once every four weeks (Q4W), supporting a potential additional, less frequent maintenance dosing option for more individualized treatment of patients with moderate-to-severe atopic dermatitis. These findings from the Phase 3 ADjoin extension trial will be presented at the 2025 Fall",
    "url": "https://finnhub.io/api/news?id=ef709aebd524fbe4a3daa148eb77ef27b3214701ac22a84a6d5d75ac065ed1ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761302700,
      "headline": "Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis",
      "id": 137215932,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "New results show Eli Lilly and Company's (NYSE: LLY) EBGLYSS (lebrikizumab-lbkz) sustained similar levels of skin clearance when administered as a single injection of 250 mg once every eight weeks (Q8W) compared with once every four weeks (Q4W), supporting a potential additional, less frequent maintenance dosing option for more individualized treatment of patients with moderate-to-severe atopic dermatitis. These findings from the Phase 3 ADjoin extension trial will be presented at the 2025 Fall",
      "url": "https://finnhub.io/api/news?id=ef709aebd524fbe4a3daa148eb77ef27b3214701ac22a84a6d5d75ac065ed1ae"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial",
    "summary": "New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. These 52-week results from the BRAVE-AA-PEDS trial – the largest Phase 3 study of its kind – will be presented at the 2025 Fall Clinical Dermatology (FCD) Conference, taking place Oct. 23-26 in Las Vegas.1",
    "url": "https://finnhub.io/api/news?id=05690680a4cc32dce58fad8a3496424229d2cf8cae87d01e63f561983d77f2f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761302700,
      "headline": "Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial",
      "id": 137215931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. These 52-week results from the BRAVE-AA-PEDS trial – the largest Phase 3 study of its kind – will be presented at the 2025 Fall Clinical Dermatology (FCD) Conference, taking place Oct. 23-26 in Las Vegas.1",
      "url": "https://finnhub.io/api/news?id=05690680a4cc32dce58fad8a3496424229d2cf8cae87d01e63f561983d77f2f6"
    }
  },
  {
    "ts": null,
    "headline": "2 Things Investors Should Know About Eli Lilly's $5 Billion Investment to Improve Its Drug Production Capacity",
    "summary": "Even aggressive tariffs may prove unable to stop this high-flying stock.",
    "url": "https://finnhub.io/api/news?id=232f7d28130691e98f507fd0e708f670ca321410a90c28a2e30b92ffaefb63fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761297300,
      "headline": "2 Things Investors Should Know About Eli Lilly's $5 Billion Investment to Improve Its Drug Production Capacity",
      "id": 137215933,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Even aggressive tariffs may prove unable to stop this high-flying stock.",
      "url": "https://finnhub.io/api/news?id=232f7d28130691e98f507fd0e708f670ca321410a90c28a2e30b92ffaefb63fc"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Agrees to Acquire Adverum Biotechnologies",
    "summary": "Eli Lilly Agrees to Acquire Adverum Biotechnologies",
    "url": "https://finnhub.io/api/news?id=e2381512bcbbb5c7505cb63157fa8d9bab4d6997474d25d591a1f07dabff784d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761295740,
      "headline": "Eli Lilly Agrees to Acquire Adverum Biotechnologies",
      "id": 137225040,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly Agrees to Acquire Adverum Biotechnologies",
      "url": "https://finnhub.io/api/news?id=e2381512bcbbb5c7505cb63157fa8d9bab4d6997474d25d591a1f07dabff784d"
    }
  }
]